Prekallikrein

Nowadays, Prekallikrein is a topic of great relevance in today's society. For decades, Prekallikrein has been the subject of interest and debate in different areas, from politics to science. There are many aspects surrounding Prekallikrein, from its origins to its global implications. In this article, we will explore some of the most relevant facets of Prekallikrein, addressing its multiple dimensions and impacts today. From its influence on the economy, through its repercussions on daily life, to its relationship with other areas of knowledge, Prekallikrein is presented as a topic of study and reflection of great importance to understand the current world. Along these lines, we will analyze some of the ideas and theories that have emerged around Prekallikrein, as well as the perspectives and debates that remain valid today.

Prekallikrein (PK), also known as Fletcher factor, is an 85,000 Mr serine protease that complexes with high-molecular-weight kininogen. PK is the precursor of plasma kallikrein, which is a serine protease that activates kinins. PK is cleaved to produce kallikrein by activated Factor XII (Hageman factor).[1]

Structure

Prekallikrein is homologous to factor XI, and similarly consists of four apple domains and a fifth, catalytic serine protease domain. The four apple domains create a disk-like platform around the base of the catalytic domain. However, unlike factor XI, prekallikrein does not form dimers.

Prekallikrein is activated to form kallikrein by factor XII cleavage of a bond homologous to the corresponding bond cleaved during factor XI activation.[2]

Prekallikrein deficiency

Hereditary deficiencies in PK are very rare. They can cause a prolonged APTT, which can be corrected by incubation of the patient’s plasma.

Deficiencies in PK can also be acquired due to some disease states, such as angioedema, infection, DIC, and sickle-cell disease.[1]

Although most cases of prekallikrein deficiency are asymptomatic, a few reports link severe prekallikrein deficiency with thrombotic phenomena and recurrent pregnancy loss. More recently, a case of prekallikrein deficiency was shown to be associated with severe mucosal bleeding.[3]

Discovery of prekallikrein

PK was initially described by Hathaway et al. in 1965 after encountering a Kentucky family who exhibited strikingly abnormal APTT results, but showed no bleeding symptoms. The family appeared to have a hereditary deficiency in an unknown coagulation factor, dubbed “Fletcher factor” after the family. In 1973 Kirk Wuepper determined that Fletcher factor and prekallikrein were the same.[4]

References

  1. ^ a b Goodnight, S.H.; Hathaway, W.E. (2001). Disorders of Hemostasis & Thrombosis: A Clinical Guide (2nd ed.). McGraw Hill Professional. ISBN 978-0071348348.
  2. ^ Hooley E, McEwan PA, Emsley J (Dec 2007). "Molecular modeling of the prekallikrein structure provides insights into high-molecular-weight kininogen binding and zymogen activation". Journal of Thrombosis and Haemostasis. 5 (12): 2461–6. doi:10.1111/j.1538-7836.2007.02792.x. PMID 17922805.
  3. ^ Dasanu CA, Alexandrescu DT (November 2009). "A case of prekallikrein deficiency resulting in severe recurrent mucosal hemorrhage". Am. J. Med. Sci. 338 (5): 429–30. doi:10.1097/MAJ.0b013e3181b270bb. PMID 19773642.
  4. ^ Online Mendelian Inheritance in Man (OMIM): KALLIKREIN B, PLASMA, 1; KLKB1 - 229000